Results 31 to 40 of about 30,153 (204)

EFFECT OF AROMATASE INHIBITOR THERAPY ON PREDICTED ADULT HEIGHT IN PREPUBERTAL BOYS WITH IDIOPATHIC SHORT STATURE [PDF]

Al-Azhar Journal of Pharmaceutical Sciences, 2015
To investigate the effect of blocking estrogen biosynthesis with anastrozole, a potent aromatase inhibitor (AI) on growth and consequently predicted adult height (PAH) in boys with high estrogen level.
Thamar Mahmoud
doaj   +1 more source

In-silico and in-vitro study reveals ziprasidone as a potential aromatase inhibitor against breast carcinoma

Scientific Reports, 2023
Aromatase enzyme plays a fundamental role in the development of estrogen receptors, and due to this functionality, the enzyme has gained significant attention as a therapeutic for reproductive disorders and cancer diseases.
Ankita Sahu, Shaban Ahmad, Khalid Imtiyaz, Ajeeshkumar Kizhakkeppurath Kumaran, Mojahidul Islam, Khalid Raza, Murugesh Easwaran, Asha Kurukkan Kunnath, Moshahid A. Rizvi, Saurabh Verma   +9 more
doaj   +1 more source

Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer [PDF]

, 2010
In women with estrogen receptor(ER)- and ErbB2(HER2)-positive breast cancer, a vicious cycle is established between ER mechanisms of action and the growth factor receptor network, leading to enhanced cell proliferation and endocrine resistance.
Bauerfeind, Ingo, Elling, Dirk, Heinemann, Volker   +2 more
core   +1 more source

Aromatase inhibitor and bone

Biomedicine & Pharmacotherapy, 2007
Aromatase is a key enzyme of intratumoral production of estrogen in breast cancers. Aromatase inhibitors are commonly used as hormone therapy in postmenopausal estrogen sensitive breast cancer patients. Type I aromatase inhibitors such as exemestane are steroidal inhibitors, which have androstenedione like structure and bind to androgen receptor with ...
Yasuhiro, Miki, Takashi, Suzuki, Hironobu, Sasano   +2 more
openaire   +2 more sources

Treatment Modalities for Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS): A Scoping Review of Prospective Treatment Studies. [PDF]

J Pain Res
Justin Andrew Bobo,1 Barbara Lubrano,2 Raul Rosario-Concepcion,3 Alejandra Cuartas-Abril,2 Pooja Advani,4 Saranya Chumsri,4,5 Barbara K Bruce2 1Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA; 2Department
Bobo JA, Lubrano B, Rosario-Concepcion R, Cuartas-Abril A, Advani P, Chumsri S, Bruce BK.   +6 more
europepmc   +2 more sources

Locally Advanced Breast Cancer Patient’s Recurrence Rates Comparison Received Steroidal and Nonsteroidal Aromatase Inhibitor Based on Luminal

Biomolecular and Health Science Journal
Introduction: Aromatase inhibitors are hormonal therapies used in menopausal breast cancer with positive progesterone receptors and/or estrogen receptors.
Desak Gede Agung Suprabawati, Bernadeta Hernik Setiyandari, Dwi Hari Susilo, Bara Kharisma, Rizki Amalia   +4 more
doaj   +1 more source

Sequencing of aromatase inhibitors [PDF]

British Journal of Cancer, 2005
Since the development of the third-generation aromatase inhibitors (AIs), anastrozole, letrozole and exemestane, these agents have been the subject of intensive research to determine their optimal use in advanced breast cancer. Not only have they replaced progestins in second-line therapy and challenged the role of tamoxifen in first-line, but there is
openaire   +2 more sources

"Ex vivo" and "in vivo" studies to assess chemical effects on steroidogenesis in fish: development and application of methods [PDF]

, 2011
The aquatic environment receives many chemical substances of natural or anthropogenic origin, which can influence the endocrine functions and health of wildlife.
a Marca Pereira, Luz Maria
core   +1 more source

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

, 2016
Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or after tamoxifen therapy is the treatment of choice for hormone-receptor–positive early breast cancer in postmenopausal women.
Ingle,, Gralow,, Rubin,, Tu,, Strasser-Weippl,, Whelan,, Beck,, Parulekar,, Winer,, Sturtz,, Robert,, Muss,, Gelmon,, Hudis,, Kaur,, Goss,, Pritchard,, Stopeck,, Wolff,   +18 more
core   +2 more sources

Breast ductal carcinoma in situ: a literature review of adjuvant hormonal therapy

Oncology Reviews, 2016
This review paper analyzed publications of adjuvant tamoxifen and aromatase inhibitor use following surgery for breast ductal carcinoma in situ (DCIS). Key endpoint analyses were risk of invasive and noninvasive malignancies and new contralateral breast ...
Stephen Kinsey-Trotman, Zumin Shi, Beverley Fosh   +2 more
doaj   +1 more source